AltheaDx, a commercial stage, precision medicine company with a leading pharmacogenomics (PGx) test for anxiety and depression, is expanding its commercial leadership team with the appointment of Jonathan Yount as SVP of Sales and Croom Lawrence as SVP of Marketing.
 
Jonathan Yount, SVP of Sales
 
Yount comes to AltheaDx with almost two decades of healthcare experience and with more than half of that focused on mental health solutions, including leadership roles at Genomind and OneOme.
 
“Roughly 1 in 5 adults in the United States experience mental illness each year. I am proud to be joining AltheaDx to help continue to raise awareness for mental health and get patients the help they need,” Yount commented.
 
Croom Lawrence, SVP of Marketing
 
Lawrence brings over two decades of experience in life science marketing, digital advertising and experience transformation. He has worked in several mental health segments, including depression, anxiety, ADHD and chronic pain. He previously served as head of strategy Americas at Merkle Health, and marketing roles at Wunderman Health, Merck Pharmaceuticals and Wyeth Pharmaceuticals.
 
“Mental Health is at the forefront of global conversations; significant momentum is building to ensure individuals suffering from mental illnesses like depression and anxiety get the right treatment regimen,” Lawrence commented. “We believe PGx testing can be a powerful lever in achieving wellness and remission when compared to standard-of-care and that now is the time to implement IDgenetix to help treat mental health disorders.”
 
“I am very excited to have Jonathan and Croom join the AltheaDx team,” said David Nikodem, CEO. “These industry veterans each have outstanding track records, both in sales, and in product branding and marketing.  Precision medicine in mental health is front and center as a potential clinical decision support tool for healthcare providers in pursuit of personalized care through genetic testing.  We believe that IDgenetix can help patients improve their chances of response and/or remission by identifying the correct medication more efficiently.”